Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 2/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.39 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.39 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL628123 | 0.77 | CYP2C9 (0.55) | CYP2C9MAOAMAOBATMHDAC3 | |
| SCHEMBL27892791 | 0.75 | HNF4A (0.47) | CYP2C9LMNAMEN1KMT2AMAPT | |
| SCHEMBL8422539 | 0.72 | WDR5 (0.43) | CYP2C9ATMLMNAMAPTALDH1A1 | |
| SCHEMBL521775 | 0.70 | MAOA (1.00) | CYP2C9MAOAMAOBATMHDAC3 | |
| SCHEMBL332581 | 0.70 | ALDH1A1 (0.57) | ATMHDAC8LMNAMAPTALDH1A1 | |
| SCHEMBL29419966 | 0.70 | MAOA (1.00) | CYP2C9MAOAMAOBATMHDAC3 | |
| SCHEMBL4923442 | 0.69 | MAOA (0.66) | CYP2C9MAOAMAOBATMHDAC3 | |
| SCHEMBL29901665 | 0.68 | CYP2C9 (1.00) | CYP2C9MAOAMAOBATMHDAC3 | |
| SCHEMBL4292264 | 0.68 | CYP2C9 (1.00) | CYP2C9MAOAMAOBATMHDAC3 | |
| SCHEMBL7970204 | 0.68 | MAOA (0.64) | CYP2C9MAOAMAOBATMHDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4221763-A1 | METHODS AND COMPOSITIONS FOR INCREASING UPTAKE, INTERNALIZATION, AND/OR RETENTION OF SMALL MOLECULE LIGANDS | Cornell University (US) | 2023-08-09 | — | — | EP | disclosed |
| EP-4217382-A1 | METHODS FOR USING COLLAGEN HYBRIDIZING PEPTIDES TO DETERMINE COLLAGEN CONTENT | 3Helix, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| WO-2022072292-A1 | METHODS AND COMPOSITIONS FOR INCREASING UPTAKE, INTERNALIZATION, AND/OR RETENTION OF SMALL MOLECULE LIGANDS | CORNELL UNIVERSITY (US) | 2022-04-07 | — | — | WO | disclosed |
| US-9260525-B2 | Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof | CHANG XIAO-JIA (US) | 2016-02-16 | — | — | US | disclosed |
| EP-2841575-A1 | ANTI-GCC ANTIBODY MOLECULES AND USE OF SAME TO TEST FOR SUSCEPTIBILITY TO GCC-TARGETED THERAPY | Millennium Pharmaceuticals, Inc. (US) | 2015-03-04 | — | — | EP | disclosed |
| WO-2013163633-A1 | ANTI-GCC ANTIBODY MOLECULES AND USE OF SAME TO TEST FOR SUSCEPTIBILITY TO GCC-TARGETED THERAPY | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-10-31 | — | — | WO | disclosed |
| EP-2603521-A2 | ANTIBODY MOLECULES TO ONCOGENIC ISOFORMS OF FIBROBLAST GROWTH FACTOR RECEPTOR-2 AND USES THEREOF | Attogen Inc. (US) | 2013-06-19 | — | — | EP | disclosed |
| US-20130142802-A1 | ANTIBODY MOLECULES TO ONCOGENIC ISOFORMS OF FIBROBLAST GROWTH FACTOR RECEPTOR-2 AND USES THEREOF | CHANG XIAO-JIA (US) | 2013-06-06 | — | — | US | disclosed |
| WO-2012021841-A2 | ANTIBODY MOLECULES TO ONCOGENIC ISOFORMS OF FIBROBLAST GROWTH FACTOR RECEPTOR-2 AND USES THEREOF | ATTOGEN INC. (US) | 2012-02-16 | — | — | WO | disclosed |
| US-20110059091-A1 | INHIBITORS OF ONCOGENIC ISOFORMS AND USES THEREOF | CHANG XIAO-JIA | 2011-03-10 | — | — | US | disclosed |
| WO-2009100105-A2 | INHIBITORS OF ONCOGENIC ISOFORMS AND USES THEREOF | ATTOGEN INC. (US) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130142802-A1 | ANTIBODY MOLECULES TO ONCOGENIC ISOFORMS OF FIBROBLAST GROWTH FACTOR RECEPTOR-2 AND USES THEREOF | FGFR2, FRS2, FGFR3 | CYP2C9 4830/4885MAOA 4276/4885MAOB 4360/4885 |
| US-20110059091-A1 | INHIBITORS OF ONCOGENIC ISOFORMS AND USES THEREOF | TP53, HRAS, BRCA1 | CYP2C9 4831/4885MAOA 3980/4885MAOB 3873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.